AU2012283924A1 - Anti-fibrotic peptides and their use in methods for treating diseases and disorders characterized by fibrosis - Google Patents

Anti-fibrotic peptides and their use in methods for treating diseases and disorders characterized by fibrosis Download PDF

Info

Publication number
AU2012283924A1
AU2012283924A1 AU2012283924A AU2012283924A AU2012283924A1 AU 2012283924 A1 AU2012283924 A1 AU 2012283924A1 AU 2012283924 A AU2012283924 A AU 2012283924A AU 2012283924 A AU2012283924 A AU 2012283924A AU 2012283924 A1 AU2012283924 A1 AU 2012283924A1
Authority
AU
Australia
Prior art keywords
fibrosis
thr
mice
cells
emt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012283924A
Other languages
English (en)
Inventor
Dattatreyamurty Bosukonda
Peter C. Keck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thrasos Innovation Inc
Original Assignee
Thrasos Innovation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thrasos Innovation Inc filed Critical Thrasos Innovation Inc
Publication of AU2012283924A1 publication Critical patent/AU2012283924A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2012283924A 2011-07-19 2012-07-19 Anti-fibrotic peptides and their use in methods for treating diseases and disorders characterized by fibrosis Abandoned AU2012283924A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161509340P 2011-07-19 2011-07-19
US61/509,340 2011-07-19
US201261662337P 2012-06-20 2012-06-20
US61/662,337 2012-06-20
PCT/US2012/047468 WO2013013085A2 (en) 2011-07-19 2012-07-19 Anti-fibrotic peptides and their use in methods for treating diseases and disorders characterized by fibrosis

Publications (1)

Publication Number Publication Date
AU2012283924A1 true AU2012283924A1 (en) 2014-02-06

Family

ID=47558730

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012283924A Abandoned AU2012283924A1 (en) 2011-07-19 2012-07-19 Anti-fibrotic peptides and their use in methods for treating diseases and disorders characterized by fibrosis

Country Status (11)

Country Link
US (2) US20140057831A1 (https=)
EP (1) EP2734220A4 (https=)
JP (1) JP2014527040A (https=)
CN (2) CN106478776A (https=)
AU (1) AU2012283924A1 (https=)
BR (1) BR112014001268A2 (https=)
CA (1) CA2842330A1 (https=)
HK (1) HK1198333A1 (https=)
IL (1) IL230510A0 (https=)
RU (1) RU2014105513A (https=)
WO (1) WO2013013085A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170232276A1 (en) * 2014-09-30 2017-08-17 Primegen Biotech, Llc Treatment of fibrosis using deep tissue heating and stem cell therapy
WO2016077539A1 (en) * 2014-11-12 2016-05-19 Thrasos Innovation, Inc. Peptides with enhanced stability and their use in methods for treating diseases
EP3289073A4 (en) * 2015-05-01 2019-07-17 University of Miami METHOD AND COMPOSITIONS FOR THE CONVERSION OF NON-ENDOCRINE PANCREATIC TISSUE IN INSULIN-PRODUCING CELLS
AU2016260190A1 (en) * 2015-05-12 2017-11-23 The Regents Of The University Of California Peptide treatment for inflammation and fibrosis
CN115925878A (zh) * 2015-06-05 2023-04-07 艾比欧公司 用于治疗纤维化的内皮抑素片段和变体
WO2019133950A1 (en) * 2017-12-30 2019-07-04 The Regents Of The University Of Colorado, A Body Corporate Smad7 for treatment and prevention of posterior capsule opacification
ES2906715T3 (es) * 2018-09-06 2022-04-20 Marine Essence Biosciences Corp Of Usa Dispositivos de biomaterial para la regeneración de tejidos guiada
US11361161B2 (en) * 2018-10-22 2022-06-14 Verint Americas Inc. Automated system and method to prioritize language model and ontology expansion and pruning
EP3996736A4 (en) * 2019-07-10 2023-05-24 Musc Foundation for Research Development ENDOSTATIN PEPTIDES FOR THE TREATMENT OF TUMOR, FIBROSIS AND ACUTE LUNG INJURY
CN111704653B (zh) * 2020-06-08 2023-10-03 深圳市图微安创科技开发有限公司 靶向于纤连蛋白衍生肽的抑制剂多肽化合物及其用途
CA3212468A1 (en) * 2021-03-16 2022-09-22 William D. Carlson Therapeutic combinations of tdfrps and additional agents and methods of use for the reversal of fibrosis
CN113069531B (zh) * 2021-04-09 2023-02-28 南开大学 一种防疤痕皮肤创伤修复用水凝胶及其制备方法
CN116768974A (zh) * 2022-03-11 2023-09-19 中山大学 用于预防和/或治疗肾纤维化的多肽化合物
WO2024081245A1 (en) 2022-10-10 2024-04-18 Therapeutics By Design, LLC Tissue differentiation factor related polypeptides (tdfrps) for the treatment of myocardial injury

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0894004B2 (en) * 1996-03-22 2007-02-21 Curis, Inc. Method for enhancing functional recovery of motor coordination, speech or sensory perception after central nervous system ischemia or trauma
WO2003106656A2 (en) * 2002-06-17 2003-12-24 Thrasos, Inc. Single domain tdf-related compounds and analogs thereof
US8410246B2 (en) * 2004-06-17 2013-04-02 Thrasos, Inc. TDF-related compounds and analogs thereof
DK2497780T3 (en) * 2005-09-20 2015-06-01 Thrasos Innovation Inc TDF-related compounds and analogs thereof
US20110275574A1 (en) * 2009-01-16 2011-11-10 Agency For Science, Technology And Research Method of inhibiting proliferation of hepatic stellate cells
WO2010099363A1 (en) * 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010128158A1 (en) * 2009-05-08 2010-11-11 Novartis Ag Diagnostic biomarkers for fibrotic disorders

Also Published As

Publication number Publication date
CN103890003A (zh) 2014-06-25
JP2014527040A (ja) 2014-10-09
BR112014001268A2 (pt) 2017-02-21
CN103890003B (zh) 2016-08-24
CA2842330A1 (en) 2013-01-24
HK1198333A1 (zh) 2015-04-02
WO2013013085A2 (en) 2013-01-24
EP2734220A4 (en) 2015-01-21
IL230510A0 (en) 2014-03-31
WO2013013085A3 (en) 2014-03-13
US20140057831A1 (en) 2014-02-27
EP2734220A2 (en) 2014-05-28
RU2014105513A (ru) 2015-08-27
CN106478776A (zh) 2017-03-08
US20160058829A1 (en) 2016-03-03

Similar Documents

Publication Publication Date Title
US20140057831A1 (en) Anti-fibrotic peptides and their use in methods for treating diseases and disorders characterized by fibrosis
US11612639B2 (en) Methods and compositions for rejuvenating skeletal muscle stem cells
AU2019366366B2 (en) Therapeutic combinations of TDFRPs and additional agents and methods of use
JP2014510758A (ja) ほ乳類において脂肪細胞を標的とするための方法および組成物
CN101883786A (zh) 人源化的notch融合蛋白组合物及治疗方法
JP2016047829A (ja) Ｔｄｆ関連化合物およびその類似体
CN113301914B (zh) 用于治疗和预防纤维化的组合物和方法
JP7535514B2 (ja) Ｄｐｅｐ－１結合剤および使用の方法
JP2008013436A (ja) 血管形成促進剤
WO2018042182A1 (en) Compositions and uses thereof
US20240123033A1 (en) THERAPEUTIC COMBINATIONS OF TDFRPs AND ADDITIONAL AGENTS AND METHODS OF USE FOR THE REVERSAL OF FIBROSIS
Rosini et al. British Society for Matrix Biology–Spring 2015 Meeting Report
Clarke Perlecan Domain V Induces VEGF Secretion in Brain Endothelial Cells Through α5β1 Integrin Dependent Mechanism a Novel Insight in Brain Tissue Recovery Following Ischemia

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ BOSUKONDA, DATTATREYAMURTY AND KECK, PETER C.

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application